1)Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E, mTOR inhibitor-associated dermatologic and mucosal problems, Clin Transplant, 2010, 24, 149-156.
2)Hu JC, Sadeghi P, Pinter-Brown LC, Yashar S, Chiu MW, Cutaneous side effects of epidermal growth factor receptor inhibitors: clinical presentation, pathogenesis, and management, J Am Acad Dermatol, 2007, 56, 317-326.
3)Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, Gutzmer R, The hand-foot-syndrome associated with medical tumor therapy - classification and management, J Dtsch Dermatol Ges, 2010, 8, 652-661.
4)Wozel G, Sticherling M, Schon MP, Cutaneous side effects of inhibition of VEGF signal transduction, J Dtsch Dermatol Ges, 2010, 8, 243-249.
5)Mahe E, Morelon E, Lechaton S, Sang KH, Mansouri R, Ducasse MF, Mamzer-Bruneel MF, de Prost Y, Kreis H, Bodemer C, Cutaneous adverse events in renal transplant recipients receiving sirolimus-based therapy, Transplantation, 2005, 79, 476-482.